Compare BANF & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | TLX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | BANF | TLX |
|---|---|---|
| Price | $111.03 | $9.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $128.00 | $21.00 |
| AVG Volume (30 Days) | ★ 115.0K | 84.5K |
| Earning Date | 01-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 13.17 | N/A |
| EPS | ★ 7.04 | 0.04 |
| Revenue | ★ $666,553,000.00 | $664,225,558.00 |
| Revenue This Year | $11.96 | N/A |
| Revenue Next Year | $3.80 | N/A |
| P/E Ratio | ★ $15.86 | $223.03 |
| Revenue Growth | 9.57 | ★ 55.35 |
| 52 Week Low | $97.02 | $8.76 |
| 52 Week High | $138.77 | $30.36 |
| Indicator | BANF | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 45.03 |
| Support Level | $107.44 | $8.76 |
| Resistance Level | $112.53 | $9.98 |
| Average True Range (ATR) | 3.73 | 0.25 |
| MACD | 0.76 | 0.06 |
| Stochastic Oscillator | 66.10 | 58.47 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.